Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So we moved today based off an Instagram post
40-50 calls?!
Innovus Pharma Announces Receipt of Notification to Commercialize Sensum+® in the European Union
Sensum+® and Zestra® Now Ready to be Commercialized in Europe
http://www.businesswire.com/news/home/20170308005449/en/
March 08, 2017 06:00 AM Eastern Standard Time
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received the CPNP notification number required to commercialize Sensum+® in all 28 member countries of the European Union.
“Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be commercialized in the European Union, and therefore, expanding our ability to enter into additional commercial partnerships.”
“We are pleased to continue to expand the commercial opportunity of our products into the European Union, the largest market after the United States,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Now that we have received the CPNP notification numbers for Sensum+® and for Zestra®, which we announced last week, Innovus has two products ready to be commercialized in the European Union, and therefore, expanding our ability to enter into additional commercial partnerships.”
Innovus Pharma currently partners Sensum+ internationally with Orimed in Canada, Tramorgen Limited in the United Kingdom, Elis Pharma in Turkey and certain select markets, BroadMed SAL for Lebanon, Ovation for Morocco, Khandelwal Laboratories, PVT, Inc. for India, Nepal, Bhutan, Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern countries, and Oz Biogenics for Myanmar and Vietnam.
Sensum+® is currently approved to be marketed and sold in 31 countries worldwide including the United States, Europe, India and Morocco. In addition to the United States, the largest market for Sensum+®, Innovus Pharma currently generates Sensum+® revenues from the following markets: the United Kingdom and Morocco.
About Sensum+® and Reduced Penile Sensitivity
Sensum+® is a non-medicated cream which moisturizes the head and shaft of the penis for enhanced feelings of sensation and greater sexual satisfaction. It is a patent-pending blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the U.S. The safety and efficacy of Sensum+® was evaluated in two post-marketing clinical survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for 14 consecutive days followed by once daily for eight weeks and as needed thereafter. Study participants reported a ~50% increase in penile sensitivity with the use of Sensum+®. For more information, visit www.sensumplus.com or www.sensumplus.co.uk for UK customers.
Reduced Penile Sensitivity (“RPS”) results form a gradual loss of penile sensitivity over time. RPS is observed in diabetic patients, patients suffering from multiple sclerosis, 20% of patients undergoing hernia surgery and circumcised men.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of Sensum+® in Europe, the sale of the Company’s other products, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contacts
Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com
just saw this
Christie hype is over. Now we wait for numbers and new deals. People don't like waiting in pennyland
One Step Vending Corp. Adds 18 Micro Market Locations in Six Weeks with Continued Accelerated Growth Expected
http://finance.yahoo.com/news/one-step-vending-corp-adds-133000282.html
good to see we are holding this level
moving up this morning
It's discussed over and over. We are waiting for the FDA.
or maybe a r/s to uplist will help
Only Fluticare will move us back up I guess
That's one way to put it. Maybe they didn't cancel their bid. We are already down more than 20%. The ride was nice while it lasted. Now back to holding bags.
looks like someone sold 750,000 shares this morning
not bad news
$INNV 8K is out
I didn't think we would see fireworks until after we got the numbers
That's not really new and in fact that Buy recommendation used to be higher on Barchart. I'm long here. I'm just surprised to see someone who was just constantly bashing the stock, now telling us it's a Buy.
You changed your mind or are you reading this somewhere?
$INNV Just added some here
so we might see a chase at the end of the day
$INNV I'm double checking but it looks like last time they release the news right after the market closed
http://www.businesswire.com/news/home/20161110006325/en/
Etrade allows you to trade before or after hours but the cost is higher
News won't hit until later in the day or after the bell
We already hit .39 today
As a long I would put in a stop loss. Might as well see where this will go since we've been here.
we have decent bid support
still waiting on FDA approval
$INNV .39 was the high of the day and were just getting started!
within a week
#1 on Breakout Boards...It's been awhile
I think 1 is a good target
60+% so far today, not mad at that
damn! Someone either knows something or is confident. We are undervalued.
looks like someone is betting on good news
It said Monday
We should be good by Summer but that is a long time in pennyland. I'm still holding from .000 so I could care less.
what's going on
picked up .0005s yesterday
Etrade offers the option